Abstract
Despite the introduction of more than 15 third generation antiepileptic drugs to the market from 1990 to the moment, about one third of the epileptic patients still suffer from refractory to intractable epilepsy. Several hypotheses seek to explain the failure of drug treatments to control epilepsy symptoms in such patients. The most studied one proposes that drug resistance might be related with regional overactivity of efflux transporters from the ATP-Binding Cassette (ABC) superfamily at the blood-brain barrier and/or the epileptic foci in the brain. Different strategies have been conceived to address the transporter hypothesis, among them inhibiting or down-regulating the efflux transporters or bypassing them through a diversity of artifices. Here, we review scientific evidence supporting the transporter hypothesis along with its limitations, as well as computer-assisted early recognition of ABC transporter substrates as an interesting strategy to develop novel antiepileptic drugs capable of treating refractory epilepsy linked to ABC transporters overactivity.
Keywords: ABC transporters, ABCB1, ABCG2, antiepileptic drugs, breast Cancer resistance Protein, drug discovery, P-glycoprotein, refractory epilepsy, transporter hypothesis.
Mini-Reviews in Medicinal Chemistry
Title:Computer-Aided Recognition of ABC Transporters Substrates and Its Application to the Development of New Drugs for Refractory Epilepsy
Volume: 17 Issue: 3
Author(s): Manuel Couyoupetrou, Melisa E. Gantner, Mauricio E. Di Ianni, Pablo H. Palestro, Andrea V. Enrique, Luciana Gavernet, Maria E. Ruiz, Guido Pesce, Luis E. Bruno-Blanch and Alan Talevi
Affiliation:
Keywords: ABC transporters, ABCB1, ABCG2, antiepileptic drugs, breast Cancer resistance Protein, drug discovery, P-glycoprotein, refractory epilepsy, transporter hypothesis.
Abstract: Despite the introduction of more than 15 third generation antiepileptic drugs to the market from 1990 to the moment, about one third of the epileptic patients still suffer from refractory to intractable epilepsy. Several hypotheses seek to explain the failure of drug treatments to control epilepsy symptoms in such patients. The most studied one proposes that drug resistance might be related with regional overactivity of efflux transporters from the ATP-Binding Cassette (ABC) superfamily at the blood-brain barrier and/or the epileptic foci in the brain. Different strategies have been conceived to address the transporter hypothesis, among them inhibiting or down-regulating the efflux transporters or bypassing them through a diversity of artifices. Here, we review scientific evidence supporting the transporter hypothesis along with its limitations, as well as computer-assisted early recognition of ABC transporter substrates as an interesting strategy to develop novel antiepileptic drugs capable of treating refractory epilepsy linked to ABC transporters overactivity.
Export Options
About this article
Cite this article as:
Couyoupetrou Manuel, Gantner E. Melisa, Di Ianni E. Mauricio, Palestro H. Pablo, Enrique V. Andrea, Gavernet Luciana, Ruiz E. Maria, Pesce Guido, Bruno-Blanch E. Luis and Talevi Alan, Computer-Aided Recognition of ABC Transporters Substrates and Its Application to the Development of New Drugs for Refractory Epilepsy, Mini-Reviews in Medicinal Chemistry 2017; 17 (3) . https://dx.doi.org/10.2174/1389557516666161013103408
DOI https://dx.doi.org/10.2174/1389557516666161013103408 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet the Editorial Board Member
CNS & Neurological Disorders - Drug Targets Huntingtons Disease: New Frontiers for Molecular and Cell Therapy
Current Drug Targets Molecular Modeling Used to Evaluate CYP2C9-Dependent Metabolism: Homology Modeling, Molecular Dynamics and Docking Simulations
Current Drug Metabolism Prorenin and the (Pro)renin Receptor in Retinal Pathology
Current Hypertension Reviews Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction
CNS & Neurological Disorders - Drug Targets A Longitudinal FDG-PET Study of Transgenic Mice Overexpressing GSK- 3β in the Brain
Current Alzheimer Research Nanotechnology in Neuroscience and its Perspective as Gene Carrier
Current Topics in Medicinal Chemistry Integrated Application of Enhanced Replacement Method and Ensemble Learning for the Prediction of BCRP/ABCG2 Substrates
Current Bioinformatics Melatonin in Autism Spectrum Disorders
Current Clinical Pharmacology Increased Risk of Falls, Fall-related Injuries and Fractures in People with Type 1 and Type 2 Diabetes - A Nationwide Cohort Study
Current Drug Safety Growing up with Midazolam in the Neonatal and Pediatric Intensive Care
Current Drug Metabolism Current Developments of Coumarin Compounds in Medicinal Chemistry
Current Pharmaceutical Design Update on Medical and Surgical Management of Intracerebral Hemorrhage
Reviews on Recent Clinical Trials Targeted Drug Delivery in Brain Tumors-nanochemistry Applications and Advances
Current Topics in Medicinal Chemistry Multiscale Modelling of Relationships between Protein Classes and Drug Behavior Across all Diseases Using the CANDO Platform
Mini-Reviews in Medicinal Chemistry Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics
Current Pediatric Reviews Molecular Cytogenetics and Cytogenomics of Brain Diseases
Current Genomics Brain Oxidative Markers in Stress: Possible New Drug Targets Against Neuroinflammation
Current Neuropharmacology A1 Receptors Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Linalool as a Therapeutic and Medicinal Tool in Depression Treatment: A Review
Current Neuropharmacology